Compare PRTA & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | BDN |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 588.8M |
| IPO Year | N/A | N/A |
| Metric | PRTA | BDN |
|---|---|---|
| Price | $9.27 | $2.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $18.86 | $4.00 |
| AVG Volume (30 Days) | 617.1K | ★ 3.5M |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 10.54% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,786,000.00 | ★ $403,561,000.00 |
| Revenue This Year | N/A | $52.95 |
| Revenue Next Year | $819.08 | $3.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.34 |
| 52 Week Low | $4.32 | $2.98 |
| 52 Week High | $17.66 | $5.90 |
| Indicator | PRTA | BDN |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 30.68 |
| Support Level | $9.69 | $2.98 |
| Resistance Level | $10.50 | $3.15 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | -0.16 | 0.00 |
| Stochastic Oscillator | 6.50 | 9.09 |
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.